Amy Glekas, Head of Field Development and Interim Head of Sales at Solvias, explores the opportunities that analytical testing can offer cell and gene therapy developers.  Cell and gene therapies (CGTs) have commanded public attention for decades. There are the big milestones, for example, the major gene therapy approvals, a decade of CAR T-induced cancer remission and the first patient-specific, in vivo gene editing treatment. However, in a more guarded investment climate, obstacles like adverse events and deaths with AAV-based gene therapies, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!